|
Increasing interest into the possible role of mitochondrial dysfunction in migraine has led some researchers to attempt to correct this malfunction using coenzyme Q10, the ubiquitous mitochondrial cofactor. A recent double-blind, placebo-controlled trial of coenzyme Q10 in 42 migraine patients found 100 mg three times daily significantly reduced the incidence of migraine (defined as a drop in incidence of 50 percent) in almost 50 percent of patients, compared to 14 percent of patients given placebo. A previous open-label study found 150 mg coQ10 per day resulted in a greater-than-50-percent decreased incidence in 61 percent of patients.
Many patients with migraines are searching for alternatives to drugs such as Depakote (an anti-seizure medication now given to prevent migraines) to help prevent migraine attacks. It appears coenzyme Q10 may be a viable alternative to the side-effect-prone prescriptions for this debilitating condition.
|
